AptarGroup to Present at Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ATR?
Source: Newsfilter
- Conference Schedule: AptarGroup will present at the Bank of America Securities 2026 Global Agriculture and Materials Conference on February 25, 2026, in Ft. Lauderdale, FL, with CEO Stephan Tanda speaking at 9:45 a.m. EST, showcasing the company's leadership in drug delivery and consumer products.
- Investor Engagement: Following this, AptarGroup will participate in the Raymond James 2026 Institutional Investors Conference on March 3, 2026, where CFO Vanessa Kanu will present at 1:05 p.m. EST, further enhancing investor relations and engagement.
- Live Webcast: The company will provide a live audio webcast and presentation materials in the 'Investors' section of its website, ensuring that investors unable to attend in person can access relevant information, thereby improving transparency and communication efficiency.
- Company Overview: AptarGroup is a global leader in drug delivery and consumer product technologies, serving attractive markets such as pharmaceuticals, beauty, food, beverage, personal care, and home care, with over 13,000 employees, demonstrating significant market influence and innovation capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 143.160
Low
133.00
Averages
145.33
High
156.00
Current: 143.160
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amcor's Strategic Outlook Post-Berry Global Merger
- Merger Impact: Amcor's all-stock merger with Berry Global, completed last April, is projected to generate approximately $23 billion in revenue over the next twelve months, and if profit margins return to levels seen three years ago, net income could exceed $1.85 billion, highlighting the scale benefits and market potential of the merger.
- Earnings Guidance: Management has guided for adjusted earnings per share of $4.00 to $4.15 for FY2026, with free cash flow expected to be between $1.8 billion and $1.9 billion, indicating a strong financial outlook post-merger that could enhance investor confidence.
- Debt Management Risks: While the company aims to reduce its debt levels of approximately $15 billion, the current debt-to-EBITDA ratio stands at 4x, indicating potential operational leverage risks when paying down debt, especially as packaging demand may soften.
- Dividend Appeal: With a dividend yield of 5.24%, Amcor offers relative attractiveness in the current market, and while dividend payments may impact option pricing, the stable cash flow and dividend policy still provide value support for investors.
See More
AptarGroup to Present at Upcoming Investor Conferences
- Conference Schedule: AptarGroup will present at the Bank of America Securities 2026 Global Agriculture and Materials Conference on February 25, 2026, in Ft. Lauderdale, FL, with CEO Stephan Tanda speaking at 9:45 a.m. EST, showcasing the company's leadership in drug delivery and consumer products.
- Investor Engagement: Following this, AptarGroup will participate in the Raymond James 2026 Institutional Investors Conference on March 3, 2026, where CFO Vanessa Kanu will present at 1:05 p.m. EST, further enhancing investor relations and engagement.
- Live Webcast: The company will provide a live audio webcast and presentation materials in the 'Investors' section of its website, ensuring that investors unable to attend in person can access relevant information, thereby improving transparency and communication efficiency.
- Company Overview: AptarGroup is a global leader in drug delivery and consumer product technologies, serving attractive markets such as pharmaceuticals, beauty, food, beverage, personal care, and home care, with over 13,000 employees, demonstrating significant market influence and innovation capabilities.
See More
AptarGroup Reports Strong Q4 2025 Earnings with Strategic Insights
- Significant Sales Growth: AptarGroup reported Q4 sales of $963 million, reflecting a 14% year-over-year increase, with core sales up 5%, indicating strong performance across all business segments, particularly in Pharma where demand is rebounding.
- Margin Pressures: Adjusted EBITDA was $191 million with a margin of 19.8%, down from the previous year, primarily due to rising production costs and shifts in product mix, highlighting challenges in cost management for the company.
- Shareholder Return Strategy: In 2025, AptarGroup returned $486 million to shareholders through buybacks and dividends, demonstrating a commitment to shareholder value, while capital expenditures represented 7% of sales, indicating a focus on high-return investments.
- Future Outlook: Management anticipates a $65 million revenue headwind from emergency medicine in 2026; nevertheless, the company remains committed to achieving a long-term core sales growth target of 7% to 11% and plans to continue capital investments and stock buybacks in the future.
See More
AptarGroup Reports Decline in Q4 Profit
- Profit Decline: AptarGroup's Q4 net profit fell to $74.34 million, or $1.13 per share, representing a 24% decrease from last year's $1.49 per share, indicating significant challenges in profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $82.06 million, or $1.25 per share, which, while relatively stable, could not offset the overall decline in net profit.
- Revenue Growth: The company's revenue increased by 13.5% year-over-year to $962.73 million, up from $848 million last year, demonstrating strong market demand and growth in product sales.
- Future Guidance: AptarGroup's EPS guidance for the next quarter is set between $1.13 and $1.21, suggesting that despite the current profit decline, the company maintains a cautiously optimistic outlook on future profitability, reflecting management's confidence in market recovery.
See More
AptarGroup Q4 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q4 Non-GAAP EPS of $1.25, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Significant Revenue Growth: The company achieved Q4 revenues of $963 million, a 13.5% year-over-year increase, surpassing analyst expectations by $84.42 million, reflecting strong market demand recovery.
- Strong Market Performance: The quarterly growth was driven by successful expansions in multiple markets, particularly in the packaging solutions sector, further solidifying its market leadership.
- Optimistic Future Outlook: AptarGroup's robust earnings report lays a foundation for future investments and expansions, with expectations to benefit from changing global consumer trends and the launch of innovative products.
See More
AptarGroup to Announce Q4 Earnings on February 5th
- Earnings Announcement Schedule: AptarGroup (ATR) is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimate at $1.23, reflecting a 17.4% year-over-year decline, while revenue is projected at $878.58 million, indicating a 3.6% year-over-year growth, showcasing potential for revenue growth.
- Historical Performance Review: Over the past two years, AptarGroup has beaten EPS estimates 75% of the time, although it has only surpassed revenue estimates 38% of the time, indicating relative stability in profitability but challenges in revenue growth.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and six downward revisions, with revenue estimates also facing six downward adjustments, reflecting a cautious market outlook on the company's future performance, which may impact investor confidence.
- Industry Conference Participation: AptarGroup will also present at the 44th Annual J.P. Morgan Healthcare Conference and at the Jefferies London Healthcare Conference in 2025, indicating the company's proactive engagement in industry discussions to enhance market presence and attract investor attention.
See More
Amcor's Strategic Outlook Post-Berry Global Merger
- Merger Impact: Amcor's all-stock merger with Berry Global, completed last April, is projected to generate approximately $23 billion in revenue over the next twelve months, and if profit margins return to levels seen three years ago, net income could exceed $1.85 billion, highlighting the scale benefits and market potential of the merger.
- Earnings Guidance: Management has guided for adjusted earnings per share of $4.00 to $4.15 for FY2026, with free cash flow expected to be between $1.8 billion and $1.9 billion, indicating a strong financial outlook post-merger that could enhance investor confidence.
- Debt Management Risks: While the company aims to reduce its debt levels of approximately $15 billion, the current debt-to-EBITDA ratio stands at 4x, indicating potential operational leverage risks when paying down debt, especially as packaging demand may soften.
- Dividend Appeal: With a dividend yield of 5.24%, Amcor offers relative attractiveness in the current market, and while dividend payments may impact option pricing, the stable cash flow and dividend policy still provide value support for investors.
See More
AptarGroup to Present at Upcoming Investor Conferences
- Conference Schedule: AptarGroup will present at the Bank of America Securities 2026 Global Agriculture and Materials Conference on February 25, 2026, in Ft. Lauderdale, FL, with CEO Stephan Tanda speaking at 9:45 a.m. EST, showcasing the company's leadership in drug delivery and consumer products.
- Investor Engagement: Following this, AptarGroup will participate in the Raymond James 2026 Institutional Investors Conference on March 3, 2026, where CFO Vanessa Kanu will present at 1:05 p.m. EST, further enhancing investor relations and engagement.
- Live Webcast: The company will provide a live audio webcast and presentation materials in the 'Investors' section of its website, ensuring that investors unable to attend in person can access relevant information, thereby improving transparency and communication efficiency.
- Company Overview: AptarGroup is a global leader in drug delivery and consumer product technologies, serving attractive markets such as pharmaceuticals, beauty, food, beverage, personal care, and home care, with over 13,000 employees, demonstrating significant market influence and innovation capabilities.
See More
AptarGroup Reports Strong Q4 2025 Earnings with Strategic Insights
- Significant Sales Growth: AptarGroup reported Q4 sales of $963 million, reflecting a 14% year-over-year increase, with core sales up 5%, indicating strong performance across all business segments, particularly in Pharma where demand is rebounding.
- Margin Pressures: Adjusted EBITDA was $191 million with a margin of 19.8%, down from the previous year, primarily due to rising production costs and shifts in product mix, highlighting challenges in cost management for the company.
- Shareholder Return Strategy: In 2025, AptarGroup returned $486 million to shareholders through buybacks and dividends, demonstrating a commitment to shareholder value, while capital expenditures represented 7% of sales, indicating a focus on high-return investments.
- Future Outlook: Management anticipates a $65 million revenue headwind from emergency medicine in 2026; nevertheless, the company remains committed to achieving a long-term core sales growth target of 7% to 11% and plans to continue capital investments and stock buybacks in the future.
See More
AptarGroup Reports Decline in Q4 Profit
- Profit Decline: AptarGroup's Q4 net profit fell to $74.34 million, or $1.13 per share, representing a 24% decrease from last year's $1.49 per share, indicating significant challenges in profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $82.06 million, or $1.25 per share, which, while relatively stable, could not offset the overall decline in net profit.
- Revenue Growth: The company's revenue increased by 13.5% year-over-year to $962.73 million, up from $848 million last year, demonstrating strong market demand and growth in product sales.
- Future Guidance: AptarGroup's EPS guidance for the next quarter is set between $1.13 and $1.21, suggesting that despite the current profit decline, the company maintains a cautiously optimistic outlook on future profitability, reflecting management's confidence in market recovery.
See More
AptarGroup Q4 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q4 Non-GAAP EPS of $1.25, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Significant Revenue Growth: The company achieved Q4 revenues of $963 million, a 13.5% year-over-year increase, surpassing analyst expectations by $84.42 million, reflecting strong market demand recovery.
- Strong Market Performance: The quarterly growth was driven by successful expansions in multiple markets, particularly in the packaging solutions sector, further solidifying its market leadership.
- Optimistic Future Outlook: AptarGroup's robust earnings report lays a foundation for future investments and expansions, with expectations to benefit from changing global consumer trends and the launch of innovative products.
See More
AptarGroup to Announce Q4 Earnings on February 5th
- Earnings Announcement Schedule: AptarGroup (ATR) is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimate at $1.23, reflecting a 17.4% year-over-year decline, while revenue is projected at $878.58 million, indicating a 3.6% year-over-year growth, showcasing potential for revenue growth.
- Historical Performance Review: Over the past two years, AptarGroup has beaten EPS estimates 75% of the time, although it has only surpassed revenue estimates 38% of the time, indicating relative stability in profitability but challenges in revenue growth.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and six downward revisions, with revenue estimates also facing six downward adjustments, reflecting a cautious market outlook on the company's future performance, which may impact investor confidence.
- Industry Conference Participation: AptarGroup will also present at the 44th Annual J.P. Morgan Healthcare Conference and at the Jefferies London Healthcare Conference in 2025, indicating the company's proactive engagement in industry discussions to enhance market presence and attract investor attention.
See More
